- cafead   Dec 05, 2023 at 10:02: AM
via Alto Neuroscience on Monday announced that its candidate ALTO-300 met its primary endpoint in a Phase IIa major depressive disorder trial, inducing significant symptomatic improvement in patients bearing a specific electroencephalogram-based biomarker.
article source
article source